Genaissance Pharmaceuticals to Present at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
2005年4月1日 - 1:30AM
PRニュース・ワイアー (英語)
Genaissance Pharmaceuticals to Present at CIBC World Markets Annual
Biotechnology and Specialty Pharmaceuticals Conference NEW HAVEN,
Conn., March 31 /PRNewswire-FirstCall/ -- Genaissance
Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that Kevin
Rakin, President and Chief Executive Officer of Genaissance, will
present at the CIBC World Markets Annual Biotechnology &
Specialty Pharmaceuticals Conference in New York at 11:30 a.m.
Eastern time on Monday, April 4, 2005. Mr. Rakin's remarks will
also be available live via an audio webcast that can be accessed
through the Company's website at: http://www.genaissance.com/ .
Genaissance Pharmaceuticals, Inc. is developing innovative products
based on its proprietary pharmacogenomic technology and has a
revenue-generating business in DNA and pharmacogenomic products and
services. Genaissance also markets its proprietary FAMILION(TM)
Test, designed to detect mutations responsible for causing Familial
Long QT and Brugada Syndromes, two causes of sudden cardiac death.
The Company's product development strategy is focused on drug
candidates with promising clinical profiles and finding genetic
markers to identify a responsive patient population. This strategy
is designed to enable Genaissance to leverage existing clinical
data and, thus, reduce the costs and risks associated with
traditional drug development and increase the probability of
clinical success and commercialization. The Company's lead
therapeutic product, vilazodone for depression, is in Phase II of
development. For more information on Genaissance, visit the
Company's website at: http://www.genaissance.com/ . DATASOURCE:
Genaissance Pharmaceuticals, Inc. CONTACT: Kevin Rakin, President
& Chief Executive Officer of Genaissance Pharmaceuticals, Inc.,
+1-203-773-1450; or Rhonda Chiger (investors) Rx Communications
Group, +1-917-322-2569; Tom Redington (media) of Redington, Inc.,
+1-203-222-7399, both for Genaissance Pharmaceuticals, Inc. Web
site: http://www.genaissance.com/
Copyright
Genaissance (NASDAQ:GNSC)
過去 株価チャート
から 5 2024 まで 6 2024
Genaissance (NASDAQ:GNSC)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Genaissance Pharmaceuticals (MM) (ナスダック市場): 0 recent articles
その他のGenaissance Pharmaceuticals, (MM)ニュース記事